Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT)

Lancet

Volumn 356, Issue 9227, 2000, Pages 366-372

  Brown, Morris J ^a   Palmer, Christopher R ^a   Castaigne, Alain ^b   De Leeuw, Peter W ^c   Mancia, Giuseppe ^d   Rosenthal, Talma ^e   Ruilope, Luis M ^f  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b University of Paris North   (France)

^c MAASTRICHT UNIVERSITY   (Netherlands)

^d UNIVERSITY OF MILAN   (Italy)

^e TEL AVIV UNIVERSITY   (Israel)

^f HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMILORIDE; ANTIHYPERTENSIVE AGENT; ATENOLOL; CALCIUM CHANNEL BLOCKING AGENT; DIURETIC AGENT; ENALAPRIL; HYDROCHLOROTHIAZIDE; NIFEDIPINE;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR RISK; CLINICAL TRIAL; DEPRESSION; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; EDEMA; EUROPE; FEMALE; FLUSHING; GOUT; HEADACHE; HEART FAILURE; HEART INFARCTION; HEART PALPITATION; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERURICEMIA; HYPOKALEMIA; HYPONATREMIA; IMPOTENCE; INJURY; ISRAEL; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; STROKE; SYNCOPE; SYSTOLIC BLOOD PRESSURE; VERTIGO;

EID: 0034729993     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)02527-7     Document Type: Article

References (29)

1. Collins R., Peto R., MacMahon S.et al. Blood pressure, stroke and coronary heart disease, part 2, short-term reductions in blood pressure. overview of randomised drug trials in their epidemiological context Lancet. 325:1990;827-838.
2. Collins R., MacMahon S. Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. Br Med Bull. 50:1994;272-298.
3. Hansson L., Lindholm L.H., Niskanen L.et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension. the Captopril Prevention Project (CAPPP) randomised trial Lancet. 353:1999;611-616.
4. Hansson L., Lindholm L.H., Ekbom T.et al. Randomised trial of old and new antihypertensive drugs in elderly patients. cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study Lancet. 354:1999;1751-1756.
5. Ramsay L.E., Williams B., Johnston G.D.et al. British Hypertension Society guidelines for hypertension management 1999: summary. BMJ. 319:1999;630-635.
6. Brown M.J., Castaigne A., De Leeuw P.W., Mancia G., Rosenthal T., Ruilope L.M. Study population and treatment titration in the International Nifedipine GITS Study. Intervention as a Goal in Hypertension Treatment (INSIGHT) J Hypertens. 16:1998;2113-2116.
7. Siscovick D.S., Raghunathan T.E., Psaty B.M.et al. Diuretic therapy for hypertension and the risk of primary cardiac arrest. N Engl J Med. 330:1994;1852-1857.
8. Brown M.J., Castaigne A., Ruilope L.M.et al. INSIGHT: International Nifedipine GITS Study: Intervention as a Goal in Hypertension Treatment. J Hum Hypertens. 10(Suppl 3):1996;S157-S160.
9. Treasure T.B., MacRae K. Minimisation. the platinum standard for trials? BMJ. 317:1998;362-363.
10. Cockcroft D.W., Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron. 16:1976;31-41.
11. Brown M.J. What does STOP-2 tell us about management of hypertension? Lancet. 355:2000;653-654.
12. Brown M.J., Castaigne A., De Leeuw P.W.et al. Influence of diabetes and type of hypertension on the response to antihypertensive treatment. Hypertension. 35:2000;1038-1042.
13. Neal B., MacMahon S. An overview of 37 randomised trials of blood pressure lowering agents among 270,000 individuals. World Health Organization-International Society of Hypertension Blood Pressure Lowering Treatment Trialists' Collaboration Clin Exp Hypertens. 21:1999;517-529.
14. Brown J., Brown M.J. Captopril Prevention Project. Lancet. 353:1999;1795-1796.
15. Arch Intern Med. 157:1997;2413-2446.
16. Staessen J., Fagard R., Thijs L.et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet. 350:1997;757-764.
17. Gong L., Zhang W., Zhu Y.et al. Shanghai trial of nifedipine in the elderly (STONE). J Hypertens. 14:1996;1237-1245.
18. Liu L., Wang J.G., Gong L., Liu G., Staessen J.A. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic Hypertension in China (Syst-China) Collaborative Group J Hypertens. 16:1998;1823-1829.
19. Dobson A.J., Evans A., Ferrario M.et al. Changes in estimated coronary risk in the 1980s: data from 38 populations in the WHO MONICA Project: World Health Organization Monitoring trends and determinants in cardiovascular diseases. Ann Med. 30:1998;199-205.
20. Kuulasmaa K., Tunstall-Pedoe H., Dobson A.et al. Estimation of contribution of changes in classic risk factors to trends in coronary-event rates across the WHO MONICA Project populations. Lancet. 355:2000;675-687.
21. Dickerson J.E., Hingorani A.D., Ashby M.J., Palmer C.R., Brown M.J. Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet. 353:1999;2008-2013.
22. Chalmers J., MacMahon S., Mancia G.et al. 1999 World Health Organization-International Society of Hypertension Guidelines for the management of hypertension. Guidelines sub-committee Clin Exp Hypertens. 21:1999;1009-1060.
23. Hansson L., Zanchetti A. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension. principal results of the Hypertension Optimal Treatment (HOT) randomised trial Lancet. 351:1998;1755-1762.
24. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. JAMA. 283:2000;1967-1975.
25. Gress T.W., Nieto F.J., Shahar E., Wofford M.R., Brancati F.L. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. N Engl J Med. 342:2000;905-912.
26. Pahor M., Guralnik J.M., Corti M-C.et al. Long-term survival and use of antihypertensive medications in older persons. J Am Geriatr Soc. 43:1995;1191-1197.
27. Furberg C.D., Psaty B.M., Meyer J.V. Nifedipine. dose-related increse in mortality in patients with coronary heart disease Circulation. 92:1995;1326-1331.
28. Pahor M., Guralnik J.M., Ferruci L.et al. Calcium-channel blockade and incidence of cancer in aged populations. Lancet. 348:1996;493-499.
29. Pahor M., Guralnik J.M., Furberg C.D., Carbonin P., Havlik R.J. Risk of gastrointestinal haemorrhage with calcium antagonists in hypertensive persons over 67 years old. Lancet. 347:1996;1061-1065.